ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer

Alexandra S. Zimmer, MD
Published Online:3:30 PM, Tue June 27, 2017

Alexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.